Eli Lilly and Company $LLY Holdings Boosted by Xponance LLC

Xponance LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 5.7% during the 4th quarter, Holdings Channel.com reports. The fund owned 208,322 shares of the company’s stock after acquiring an additional 11,263 shares during the period. Eli Lilly and Company accounts for about 1.7% of Xponance LLC’s portfolio, making the stock its 10th largest position. Xponance LLC’s holdings in Eli Lilly and Company were worth $223,879,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares in the last quarter. 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares in the last quarter. Finally, Miller Global Investments LLC purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $33,000. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research analyst reports. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price target for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Wolfe Research reissued an “outperform” rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Berenberg Bank boosted their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Finally, Cantor Fitzgerald boosted their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,227.74.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group Bank raised its EPS estimates for Eli Lilly’s FY2026 and FY2027, signaling continued confidence in earnings growth above current consensus expectations. This kind of analyst revision can support the stock by reinforcing the view that Lilly’s profits are still expanding rapidly.
• Positive Sentiment: The FDA approved extended once-every-eight-weeks maintenance dosing for Ebglyss in eczema care, which broadens Lilly’s dermatology franchise and improves convenience for patients. Investors may see this as another incremental growth driver beyond the company’s obesity and diabetes leadership. Article Title
• Positive Sentiment: Lilly also reported encouraging top-line results for Foundayo (orforglipron), its oral GLP-1 candidate, with evidence of meaningful weight-loss progress in clinical testing. That strengthens the market’s belief that Lilly can extend its obesity-drug dominance with a convenient pill format. Article Title
• Positive Sentiment: Management continues to expand the pipeline, including new Phase 2 trials in chronic pain and osteoarthritis, which adds long-term optionality for the stock. Article Title
• Neutral Sentiment: Broader healthcare stocks were higher in late-afternoon trading, which may be providing a favorable sector backdrop, though it is not Lilly-specific.
• Neutral Sentiment: Reuters reported that some U.S. employers may drop coverage of GLP-1 obesity drugs in 2027 as usage rises, a reminder that reimbursement pressure could eventually temper demand even for leading products like Zepbound and Foundayo. Article Title

Eli Lilly and Company Stock Up 2.2%

Shares of LLY opened at $1,161.75 on Friday. The stock has a market capitalization of $1.09 trillion, a price-to-earnings ratio of 41.27, a price-to-earnings-growth ratio of 1.24 and a beta of 0.53. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The business’s 50 day simple moving average is $994.84 and its 200-day simple moving average is $1,015.87. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.